Find any stock by ticker or company name
Barcha huquqlar himoyalangan.
24.86
0.00 (0.00%)
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics to present at Citi's 2026 Biopharma Back to School Conference and participate in 21st Annual Wells Fargo Healthcare Conference.
Seaport Therapeutics leverages its Glyph platform to transform clinically validated molecules with poor delivery into proprietary, patent-protected prodrugs, reducing biological risk. GlyphAllo's Phase 2b BUOY-1 trial in MDD targets a differentiated profile, with top-line data expected in H1 2027 and a focus on anxious distress subpopulations. GlyphAgo's strong Phase 1 PK data and platform repeatability support SPTX's strategy, with Phase 2a in GAD set for H2 2026 and registration-enabling studies to follow.
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress.
There is no data to display
